BIIB
Price
$258.05
Change
+$3.03 (+1.19%)
Updated
Sep 26, 6:59 PM EST
27 days until earnings call
BMY
Price
$58.55
Change
-$0.63 (-1.06%)
Updated
Sep 26, 6:59 PM EST
29 days until earnings call

Compare predictions BIIB vs BMY

Header iconBIIB vs BMY Comparison
Open Charts BIIB vs BMYBanner chart's image
Biogen
Price$258.05
Change+$3.03 (+1.19%)
Volume$454.05K
CapitalizationN/A
Bristol-Myers Squibb
Price$58.55
Change-$0.63 (-1.06%)
Volume$2.7M
CapitalizationN/A
View a ticker or compare two or three
BIIB vs BMY Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
BIIB vs. BMY commentary
Sep 27, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongSell and BMY is a StrongSell.

COMPARISON
Comparison
Sep 27, 2023
Stock price -- (BIIB: $258.05 vs. BMY: $58.54)
Brand notoriety: BIIB and BMY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 91% vs. BMY: 84%
Market capitalization -- BIIB: $36.93B vs. BMY: $123.59B
BIIB [@Pharmaceuticals: Major] is valued at $36.93B. BMY’s [@Pharmaceuticals: Major] market capitalization is $123.59B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $524.29B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $80.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileBMY’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • BMY’s FA Score: 1 green, 4 red.
According to our system of comparison, BMY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 4 TA indicator(s) are bullish.

  • BMY’s TA Score: 4 bullish, 4 bearish.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +0.54% price change this week, while BMY (@Pharmaceuticals: Major) price change was -0.15% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.75%. For the same industry, the average monthly price growth was -4.10%, and the average quarterly price growth was -2.82%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 24, 2023.

BMY is expected to report earnings on Oct 26, 2023.

Industries' Descriptions

@Pharmaceuticals: Major (-2.75% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
A.I.dvisor published
a Summary for BIIB with price predictions.
OPEN
A.I.dvisor published
a Summary for BMY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
BMY($124B) has a higher market cap than BIIB($36.9B). BMY has higher P/E ratio than BIIB: BMY (15.72) vs BIIB (13.91). BIIB YTD gains are higher at: -6.814 vs. BMY (-16.585). BMY has higher annual earnings (EBITDA): 19.8B vs. BIIB (3.82B). BMY has more cash in the bank: 8.73B vs. BIIB (6.08B). BIIB has less debt than BMY: BIIB (6.59B) vs BMY (39.2B). BMY has higher revenues than BIIB: BMY (45.2B) vs BIIB (9.97B).
BIIBBMYBIIB / BMY
Capitalization36.9B124B30%
EBITDA3.82B19.8B19%
Gain YTD-6.814-16.58541%
P/E Ratio13.9115.7288%
Revenue9.97B45.2B22%
Total Cash6.08B8.73B70%
Total Debt6.59B39.2B17%
FUNDAMENTALS RATINGS
BIIB vs BMY: Fundamental Ratings
BIIB
BMY
OUTLOOK RATING
1..100
554
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
10058
SMR RATING
1..100
4739
PRICE GROWTH RATING
1..100
5661
P/E GROWTH RATING
1..100
6285
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (93) in the Biotechnology industry. This means that BMY’s stock grew significantly faster than BIIB’s over the last 12 months.

BMY's Profit vs Risk Rating (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that BMY’s stock grew somewhat faster than BIIB’s over the last 12 months.

BMY's SMR Rating (39) in the Pharmaceuticals Major industry is in the same range as BIIB (47) in the Biotechnology industry. This means that BMY’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's Price Growth Rating (56) in the Biotechnology industry is in the same range as BMY (61) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to BMY’s over the last 12 months.

BIIB's P/E Growth Rating (62) in the Biotechnology industry is in the same range as BMY (85) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMY
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
53%
Momentum
ODDS (%)
Bearish Trend 1 day ago
52%
MACD
ODDS (%)
Bearish Trend 1 day ago
54%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
51%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
49%
Advances
ODDS (%)
Bullish Trend 7 days ago
57%
Declines
ODDS (%)
Bearish Trend 10 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
62%
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KHC34.500.18
+0.52%
Kraft Heinz Company (The)
AMSF51.00-0.65
-1.26%
AMERISAFE
BXMT21.90-0.45
-2.01%
Blackstone Mortgage Trust
TUSK4.63-0.10
-2.11%
Mammoth Energy Services
GAME2.08-0.09
-4.31%
GameSquare Holdings

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AZN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+1.19%
AZN - BIIB
34%
Loosely correlated
-1.04%
JNJ - BIIB
32%
Poorly correlated
-0.77%
MRK - BIIB
29%
Poorly correlated
-0.43%
PFE - BIIB
29%
Poorly correlated
-1.76%
ABBV - BIIB
27%
Poorly correlated
-0.48%
More